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Abstract
C-C Chemokine receptor five knockout (Ccr5-/-) mice develop fewer experimental pulmonary
metastases than wild type (WT) mice. This phenomenon was explored by applying gene-
expression profiling to the lungs of mice with these metastases. Consequently, Erythroid
Differentiation Regulator 1 (Erdr1) was identified as upregulated in the WT mice. Though
commonly associated with bone marrow stroma, Erdr1 was differentially expressed in WT
pulmonary mesenchymal cells (PMCs) and murine embryonic fibroblasts (MEFs). Moreover, the
Ccr5 ligand Ccl4 increased its expression by 3.36 ± 0.14 fold. Ccr5 signaling was dependent on
the Map2k but not the Pi3k pathway since treatment with U0126 inhibited upregulation of Erdr1
but treatment with LY294002 increased the expression by 3.44 ± 0.92 fold (p < 0.05). Erdr1's
effect on B16-F10 melanoma metastasis was verified by the adoptive transfer of WT MEFs into
Ccr5-/- mice. In this model, MEFs that had been transduced with Erdr1 shRNA lowered metastasis
by 33% compared to control transduced MEFs. The relevance of ERDR1 on human disease was
assessed by co-culturing chronic lymphocytic leukemia (CLL) cells with M2-10B4 stromal cells
that had been transfected with shRNA or control plasmids. After 96 hours of co-culture, the cell
counts were higher with control cell lines compared with Erdr1 knockdown lines (OR 1.88 ± 0.27,
2.52 ± 0.66 respectively). This increase was associated with a decrease in apoptotic cells (OR 0.69
± 0.18, 0.58 ± 0.12 respectively).
Implications—Therefore, ERDR1 is a stromal-derived factor that promotes cancer cell survival
in vitro and in an experimental metastasis model.
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Over the past ten years, evidence has emerged highlighting the importance of stromal cells
in cancer progression (1-4). During metastasis, the associated stroma is remodeled by the
activation of fibroblasts and the recruitment of bone-marrow derived cells. While the
mediators of this process continue to be elucidated, several are well established including
PDGFR ligands (5), MMP-9 (6), IL-6 (7), S100A4 and S100A8 (8, 9). These mediators are
of clinical importance because they provide therapeutic targets, which may be critical for the
treatment of chemotherapy-resistant tumors.
We have previously shown that stromal cells expressing Ccr5 contribute to the formation of
a metastasis-promoting stroma. Specifically, the activation of Ccr5 on pulmonary
mesenchymal cells (PMCs) leads to the induction of Mmp-9 (10). These results have been
extended by others studying the Ccr5 ligand Ccl3. In addition to Mmp9, tumors in Ccr5-/-
and Ccl3-/- mice produce less Hgf and accumulate fewer monocytes and T cells than tumors
in WT mice (11). Ccr5 expression by the host also contributes to the survival of cancer cells
by inhibiting apoptosis (12).
Given the importance of CCR5, we decided to further investigate this mechanism by
comparing gene expression in WT vs. Ccr5-/- lungs after the injection of B16-F10 melanoma
cells. These experiments led to our characterization of the gene erythroid differentiation
regulator 1 (Erdr1) as a metastasis-promoting signal.
ERDR1 was first isolated from the myelomonocytic cell line WEHI-3B as a cytokine that
induced hemoglobin synthesis (13). However, a wider biologic function was suggested by
its expression in other cell types including murine fibroblasts, lymphoma cells, and human
peripheral blood mononuclear cells (14). In addition to hemoglobin synthesis, ERDR1 also
acts as a survival signal during periods of cellular stress. This function has been established
in erythroblasts, granulocyte/monocyte progenitors, and hematopoietic stem cells (14). A
greater significance of this gene is also implied by its differential expression on a number of
cDNA microarrays including those analyzing brain inflammation, neurodegeneration
(15-17) and development (18, 19).
In this report, we show that ERDR1-expressing stroma promotes cancer cell survival in vitro
and during cancer cell invasion. Furthermore, the gene is upregulated by chemokine ligand
binding to CCR5. Therefore, ERDR1 may be an innovative therapeutic target either directly
or indirectly by inhibiting CCR5.
Experimental Procedures
Mice
C57BL/6J (WT) mice were purchased from Jackson Laboratories (Bar Harbor, ME). The
generation of B6.129P2-Ccr5tm1Kuz/J (Ccr5-/-) mice has been described previously (20).
Males and females between eight and twelve weeks were used in these experiments.
Controls and experimental groups were balanced by age and gender. All animals were
housed in pathogenfree conditions and all experiments were conducted using protocols
approved by the Institutional Animal Care and Use Committee of the University of North
Carolina at Chapel Hill.
Cells
B16-F10 melanoma, A293T, and M2-10B4 cells were purchased from American Type
Culture Collection (ATCC, Rockland, MD). Upon receipt, these cells were expanded by
three to four passages and were frozen into aliquots to maintain their uniformity and
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veracity. B16-F10 cells were additionally verified by melanin production. Aliquots were
passaged twice after thawing and before use.
Isolation of pulmonary mesenchymal cells (PMCs) was performed as previously described
(10). In all experiments, PMCs were used within two passages of isolation. Murine
embryonic fibroblasts (MEFs) were harvested from day E 13.5 embryos as described
elsewhere (21) and were transduced after two to five ex vivo passages.
All murine cell types were cultured in DMEM supplemented with 10% FBS and 1%
penicillin/streptomycin (Gibco, Grand Island, NY). Human CLL cells were cultured in
complete RPMI (Gibco) with 10% FBS.
Flow cytometry and cell sorting
Identification of PMC populations was accomplished by incubating the cells with anti-
Thy-1.2-PECy7 (eBioscience, San Diego, CA) and anti-CD45-eFluor450 (eBioscience)
antibodies for 15 minutes at room temperature. CD45+ cells were sorted by the UNC Flow
Cytometry Facility. Apoptotic cells were identified by staining the cells with propidium
iodide and Annexin-V- APC (eBioscience) for 15 minutes at room temperature.
Fluorescence was measured on the MACSQuant Analyzer (Miltenyi, Bergisch Gladbach,
Germany) and was analyzed using Summit software (Beckman Coulter Brea, CA).
In Vitro Experiments
PMCs were maintained overnight in serum-free conditions prior to chemokine treatment.
The following day, 50 ng/ml of Ccl4 (Peprotech Inc., Rocky Hill, NJ) was added. mRNA
was harvested 24 and 48 hours after stimulation. Intracellular signaling pathways were
investigated by adding 10 μM of the MAP2K inhibitor U0129 or 20 μM of the PI3K
inhibitor LY294002 (Cell Signaling Technology, Danvers, MA). Both inhibitors were
reconstituted in DMSO before being diluted with media. Control wells were treated with
media containing equivalent amounts of DMSO.
Apoptosis was induced with staurosporine treatment. For these experiments, MEFs were
seeded onto 6-well plates 48 hours after transduction. After resting overnight, the cells were
incubated with 100 nM staurosporine plus 20 μM Z-VAD-FMK (inhibitor) or Z-FA-FMK
(control peptide) (Sigma-Aldrich, St. Louis, MO). Apoptosis was measured 24 hours later
using annexin V and PI as described above.
In Vivo Experiments
Cell transfer experiments were performed by tail vein injection in a total volume of 200μl of
PBS. 4 × 105 MEFs were injected followed by 7.5 × 105 B16-F10 cells. The mice were
given 48 hours rest between injections. Fourteen days after melanoma injection, the lungs
were harvested and insufflated with Fekete's solution. Lung metastatic nodules were counted
by an individual blinded to the experimental group (10).
eGFP expression by cells within the lung was measured using an eGFP ELISA (Cell
BioLabs, San Diego, CA). To do so, the left upper lobe of the lung was harvested after
perfusing the animal with PBS. These samples were then homogenized in the presence of
PBS and a protease-inhibitor cocktail (Roche, Pleasanton, CA). Supernatants were added to
the ELISA plate following two centrifugation steps. The plates were then processed
according to the manufacturer's instructions.
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Gene array experiments were performed on the lungs of WT and Ccr5-/- mice. These lungs
were harvested at 6, 24, and 48 hours after intravenous injection with 7.5 × 105 B16-F10
melanoma cells. Passenger leukocytes were removed by perfusing the mice with PBS
warmed to 37o C. The samples were the flash frozen and stored in liquid nitrogen prior to
processing. mRNA isolation and cDNA formation have been previously described (10). The
resulting cDNA was normalized by amount, pooled by time point, and hybridized to
Affymetrix GeneChip® Genome 430 Arrays (six arrays in total) (Affymetrix, Santa Clara,
CA). Gene expression was analyzed using GeneSpring software (Agilent Technologies,
Santa Clara, CA). All microarray data are MIAME compliant and have been deposited at
GEO (GEO ID: GSE51422). Confirmation of the microarray studies was performed by
semi-quantitative RT-PCR as previously described (10). (See Supplementary Experimental
Procedures for primer sequences).
PMC or MEF mRNA was amplified by RT-PCR using the reagents and primers given in the
Supplementary Experimental Procedures. Real-time PCR was performed using SYBR Green
Master Mix (Applied Biosystems, Foster City, CA). For analysis of PMC or MEFs, Erdr1
expression was calculated relative SDHα. This housekeeping gene was chosen from eight
candidate genes based on its expression compared to Erdr1 and its stability under
experimental conditions. For analysis of the whole lung, expression was normalized to the
amount of mRNA as measured by the Qubit fluorometer (Invitrogen, Grand Island, NY).
Cloning and Manipulation of Erdr1 expression
Full-length Erdr1 was cloned from PMC and MEF cDNA and sequenced as described in the
Supplementary Experimental Procedures. For expression by lentiviral vectors, Erdr1 cDNA
was cloned into a pLenti7.3 plasmid (Invitrogen) containing either the EF1α or CMV
promoter (see Supplementary Experimental Procedures). Lentiviral vectors were packaged
in A293T cells according to the manufacturer's instructions.
Erdr1 expression was inhibited by transducing target cells with shRNA. Candidate shRNA
sequences were confirmed by the UNC Genome Analysis facility. These sequences and a
scrambled control sequence were cloned into pHSPG vectors (see Supplementary
Experimental Procedures) (22, 23). HSPG viral vectors were packaged as described in the
Supplementary Experimental Procedures. PMCs and MEFs were transduced by spin
inoculation in six-well plates with polybrene (4 μg/mL) (Sigma) and virus (MOI=5).
Transduction efficiency was assessed by measuring the percentage of eGFP positive cells by
flow cytometry. Knockdown efficiency was determined by real time PCR. Of the candidate
sequences tested, two were chosen for this study based on the degree of Erdr1 inhibition.
Over-expression of Erdr1 was accomplished using the GeneSwitch vector system
(Invitrogen). After cloning, Erdr1 and LacZ control plasmids were linearized with SAPI
(NEB, Ipswich, MA). One μg of plasmid DNA was transfected using Qiagen Attractene
reagent according to the manufacturer's instructions (Qiagen, Germantown, MD). After an
eight hour incubation, RU486 (one μM final concentration) was added to the cells. 72 hours
later, expression of Erdr1 was measured by real time PCR in an aliquot of these cells. The
remainder was injected into mice as described above.
Analysis of CLL Samples
Peripheral blood samples were obtained from CLL patients through UNC's Tissue
Procurement Facility. Only patients with more than 95% lymphocytes on their complete
blood count differential were included; all patients were consented according to policies of
UNC Institutional Review Board. Peripheral blood monocytes (PBMCs) were isolated from
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EDTA samples using LSM (MP Biomedicals, Santa Ana, CA) according to the
manufacturer's instructions. Cells were washed five times, resuspended in 10% RPMI, and
maintained at 5% CO2 and 37o overnight. On the day of collection, 104 M2-10B4 cells in
10% DMEM were added to six-well plates and were treated with two μg/ml mitomycin C
(Sigma). The following day, the wells were washed twice with warm PBS and 106 PBMCs
were added in 10% RPMI.
Ninety-six hours after the initiation of the co-culture, peripheral blood cells were harvested
and analyzed for apoptosis with Annexin V and propidium iodide. M2-10B4 cells were
excluded by their eGFP expression.
Statistics
Unless otherwise stated, data are presented as the mean of measurements taken from three or
more separate experiments. Statistical error for these means is presented as ±1 SEM. p
values were determined by Mann-Whitney test; values < 0.05 were considered significant.
The Bonferroni correction was applied to experiments with more than two experimental
groups.
Results
Erdr1 has greater expression in the lungs and PMCs of WT than Ccr5-/- mice
We searched for genes that might be critical for the CCR5-dependent promotion of
metastasis by comparing mRNA from WT and Ccr5-/- mice that were intravenously injected
with B16-F10 melanoma cells. Analysis revealed 11 candidate genes that were differentially
expressed at 6, 12, and 24 hours after injection (Fig. 1A). Semi-quantitative RT-PCR was
then performed on the unpooled cDNA samples using primers for each of these genes
(Supplemental Fig. S1). Erdr1 expression was detected in 100% of WT mice (n=14); but in
0 (n=13) of the Ccr5-/- mice (Fig. 1B). This same pattern was also seen in control mice that
did not receive tumor injections (Fig. 1C). The expression patterns for the remaining ten
genes were much more heterogeneous. For example, Mid1 was detectable in 50% of the WT
and 38.5% of the Ccr5-/- mice while Ccr9 was evident in 64.3% of the WT and 46.2% of the
Ccr5-/- mice. As a result, we chose to further characterize the role of ERDR1 in the
promotion of lung metastasis.
Semi-quantitative RT-PCR was then performed on the unpooled cDNA samples using
primers for each of these genes (Supplemental Fig. S1). Erdr1 expression was detected in all
14 WT mice; however, expression was near or below the threshold of detection for all 13
Ccr5-/- mice (Fig. 1B). This same pattern was also seen in control mice that did not receive
tumor injections (Fig. 1C). The expression patterns for the remaining ten genes were much
more heterogeneous. As a result, we chose to further characterize the role of ERDR1 in the
promotion of lung metastasis.
We have previously shown metastases can be increased in Ccr5-/- mice with the adoptive
transfer of WT pulmonary mesenchymal cells (PMCs) but not Ccr5-/- PMCs (24). Since this
disparity might have been due to the increased expression of Erdr1 in the WT cells, gene
expression was measured in WT and Ccr5-/- PMCs using real-time PCR. As was the case for
the whole lung, Erdr1 expression was 6.4 ± 2.7 fold higher in the WT PMCS than the
Ccr5-/- cells (p < 0.001) (Fig. 1D).
Given the limited published data on Erdr1, the sequence of the gene expressed by PMCs
was compared with that described in WEHI-3B cell line (13). As shown in Supplemental
Fig. S2, the open reading frame in the Erdr1 consensus sequence was 100% identical to the
sequence found in the WEHI-3B cell line.
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CCL4 induces the expression of Erdr1 in CCR5-expressing PMCs
We established an in vitro association between ERDR1 and CCR5 by treating PMCs with 50
ng/ml of the Ccr5-specific chemokine Ccl4. As measured by real-time PCR, Erdr1
expression in WT PMCs was increased by 1.33 fold ± 0.06 (p < 0.05) after 24 hours of
incubation with Ccl4. By 48 hours, expression had increased by 3.36 fold ± 0.14 (p < 0.001)
(Fig. 2A). Ccl4 did not increase expression of Erdr1 in Ccr5-/- PMCs.
The relationship between ERDR1 and CCL4 was verified by inhibiting the intracellular
signaling pathways induced by CCL4. To do so, WT PMCs were treated with the MAP2K
inhibitor U0126 or the PI3K inhibitor LY294002. As shown in Fig 2B, Ccl4 increased
expression of Erdr1 following treatment with LY294002 by 3.44 ± 0.92 fold (p < 0.05), but
not with U0126 (Fig. 2B).
Cultured PMCs contain three different populations of stromal cells, which can be
differentiated by their expression of CD45 and Thy-1 (10). Flow cytometric analysis
identified fibrocytes as CD45 positive with intermediate expression of Thy-1. Fibroblasts,
on the other hand, were CD45- and could be separated into two additional populations based
on Thy-1 expression (Fig. 2C). All three of these WT populations expressed more Erdr1
than their Ccr5-/- counterparts (Fig. 2D).
Fibrocytes also express more CCR5 than fibroblasts (10). Given this observation, fibrocytes
were expected to have a greater response to CCL4 than fibroblasts. This hypothesis was
tested by treating PMCs with Ccl4 for 48 hours and then by sorting the cells by Thy-1 and
CD45 expression. As predicted, WT CD45+ fibrocytes increased their expression of Erdr1
by 14.2 fold ± 2.9. Erdr1 expression was not induced in the Ccr5-/- fibrocytes or fibroblasts
(p < 0.01) (Fig. 2E).
Experimental pulmonary metastasis is reduced after knockdown of Erdr1
The effect of ERDR1 on metastasis was directly tested by manipulating the amount of
ERDR1 expressed by stromal cells within the lung prior to injection with B16 F10 cells. In
the first series of experiments, metastasis was measured in Ccr5-/- mice injected with Erdr1
knockdown or control stromal cells. To this end, we selected two HSPG retroviral vectors
carrying different Erdr1-specific shRNA sequences and one vector carrying scrambled
shRNA control sequence (Supplemental Fig. 3A).
This strategy was applied to murine embryonic fibroblasts (MEFs) rather than PMCs for
several reasons. First, MEFs expressed greater amounts of Erdr1 than PMCs (Supplemental
Fig. 3B). As a result, shRNA treatment would generate a greater difference in Erdr1
expression and amplify effects of the gene on metastasis. Second, PMCs transduced with
Erdr1 shRNAs expanded poorly (Supplemental Fig. 3C). This constraint limited the
technical feasibility of these experiments and raised questions about the persistence of the
knock-down cells in vivo. Despite these differences, unmanipulated WT MEFs did promote
metastasis in Ccr5-/- mice similar to that found by injecting WT PMCs (Supplemental Fig.
3D). Transduction of MEFs also produced viable cells with a mean reduction in Erdr1
expression of 55% ± 1.0% for shRNA &num;1 and 70% ± 6.5% for shRNA &num;2 (Fig
3A).
Compared to the control MEFs, Erdr1 knockdown MEFs were associated with a 32.7% and
32.4% reduction in lung metastasis (p<0.05) (Fig. 3B, C). This result suggested that ERDR1
acts to promote metastasis or inhibition of ERDR1 reduces metastasis. The latter was ruled
out by transferring Erdr1 knockdown MEFs into WT mice. There were no measurable
differences in metastasis when comparing shRNA knockdown MEFs to control transduced
MEFs (Fig. 3D).
Mango et al. Page 6













The transduction efficiency varied from experiment to experiment. This observation
prompted the comparison of mice that received greater than 50% transduced MEFs with
those that received less than 50%. Ccr5-/- mice that received greater than 50% shRNA
transduced MEFs had significantly fewer metastases (shRNA&num;1 = 53.3%,
shRNA&num;2 = 50.4%) than those that received less than 50% transduced cells
(shRNA&num;1 =23.8%, shRNA&num;2 =15.4%) (Fig. 3E). Thus, a greater number of
shRNA transduced MEFs were associated with fewer metastases.
Our observation that inhibition of ERDR1 inhibits metastasis could also be explained by
differences in the survival of the injected MEFs. The number of viable MEFs expressing
eGFP in the lung was determined by measuring eGFP in the lung by ELISA. This assay
revealed no differences in the lungs from animals injected with control or Erdr1 shRNA
transduced MEFs. Animals receiving transduced MEFs had significantly more eGFP than
animals injected with unmanipulated MEFs at 24 hours (p<0.01). Differences in eGFP
amount were lost at 48 hours (Fig. 3F). Our technique was further confirmed by measuring
Erdr1 expression in the lungs of Ccr5-/- mice after injection with shRNA or controlled
transduced MEFs. 24 hours after injection with 4 × 105 control MEFs, Erdr1 expression was
increased by 2.5 ± 0.8 fold over shRNA transduced MEFs (Fig. 3G).
ERDR1 promotes survival of chronic lymphocytic leukemia cells
The ability of ERDR1 to promote experimental metastasis is not well explained by its
principle function of hemoglobinization. Other functions have not been well described. Our
experience with MEFs suggested ERDR1 could oppose apoptosis. Though no differences in
apoptosis were noted at baseline, ERDR1 countered apoptosis when cells were challenged
with staurosporine, an apoptotic stimulus. In these experiments, Erdr1 knockdown by
shRNA &num;1 and &num;2 was associated with a greater percentage of apoptotic cells
than control transduction (32.7% ± 1.8% vs. 40.2% ± 1.7% vs. 48.1% ± 2.1%, p < 0.05).
These differences in apoptosis were lost when these cells were treated with the pan-caspase
inhibitor Z-VAD (Fig.4A).
ERDR1's effect on apoptosis was also tested by co-culturing primary chronic lymphocytic
leukemia (CLL) cells with M2-10B4 stromal cells. Without stromal cell support, CLL cells
undergo apoptosis within 48 to 72 hours. Therefore, ERDR1's contribution to this process
could be examined by comparing CLL cell survival using stromal cells treated with
Erdr1shRNAs. Accordingly, we selected stable control and knock-down clones based on
similarities in proliferation and on expression of Erdr1. Compared with the non-targeted
line, the Erdr1 expression was 76.8% ± 3.3% for shRNA &num;1 and 74.0% ± 6.5% for
shRNA &num;2 (p<0.05) (Fig. 4B).
At 96 hours, the cell counts were higher when the CLL cells were co-cultured with control
cell lines compared with Erdr1 knockdown lines (OR 1.88 ± 0.27, 2.52 ± 0.66 respectively,
p < 0.05) (Fig. 4C). This increase in total cell number was associated with a decrease in the
percentage of apoptotic cells (OR 0.69 ± 0.18, 0.58 ± 0.12 respectively) (Fig. 4D).
Discussion
Therapeutic strategies that disrupt the tumor stroma have been limited by the lack of suitable
targets. Our group searched for such a target by comparing the gene expression from the
lungs of WT and Ccr5-/- mice since Ccr5 signaling by the host stromal cells promotes
metastasis (24). This search identified Erdr1 as overexpressed in the lungs of WT compared
to Ccr5-/- mice injected with tumor cells. Though previously associated with the bone
marrow stroma, the expression of this gene in the lung stroma was established by detecting
it in PMCs, which are made up of both fibroblasts and fibrocytes. The reintroduction of
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ERDR1 into Ccr5-/- mice by the adoptive transfer of MEFs restored the pro-metastatic
stroma. Furthermore, we found that ERDR1 inhibited apoptosis of human CLL cells.
Therefore, we propose that ERDR1 expression by stromal cells promotes invasion and
survival of cancer cells by inhibiting apoptosis of these cells.
We chose to study Erdr1 since it was one of 11 genes that were differentially expressed in
the lung during the first 48 hours of tumor growth. Several of these 11 genes have already
been associated with cancer progression. For example, Cyr61 has been associated with poor
prognosis in squamous cell cancers of the head and neck (25) and esophagus (26). CCR2 has
been linked to breast cancer metastasis (27). The inclusion of genes with known
tumorpromoting properties substantiates the robustness of our approach. Nevertheless, of
these 11 genes, only Erdr1 demonstrated differential expression in all 27 mice tested.
The identification of ERDR1 was somewhat unexpected since previous work had focused on
its role in hemoglobin synthesis. However, a broader physiologic role for this gene is
implied by its expression in a wide variety of developing and mature tissues. In addition to
the bone marrow (13), gene expression has been demonstrated in the mammary gland,
spleen, and lymph node (28). Others have found Erdr1 expression during retinal
development (29), gonadal differentiation (18), liver development (30) and placental
morphogenesis (31). The expression of Erdr1 during development is noteworthy because it
suggests a potential role in malignancy. Cancer gene expression often recapitulates tissue-
specific development programs (32, 33). Consequently, developmental genes are candidate
oncogenes. In this context, the contribution of ERDR1 to cancer cell survival may not be
surprising.
These data provide an additional mechanism by which CCR5 promotes cancer progression,
namely by the induction of Erdr1. The capacity of Ccr5 to increase Erdr1 expression was
demonstrated in PMCs following treatment with Ccl4, a ligand with specificity for Ccr5.
This expression was the greatest in the migrating fibrocyte population, which was expected
given their increased expression of Ccr5. This observation is notable since fibrocytes have
the greater effect on metastasis than either Thy-1+ or Thy-1- fibroblasts (10).
ERDR1's role in cancer progression is complex. Jung et al have shown that recombinant
ERDR1 suppresses the invasion of human gastric cancer cells (34). This observation follows
reports that ERDR1 inhibits metastasis of melanoma cells (35). Our data can be harmonized
with these apparently contradictory studies by noting major differences in the experimental
methods. Our studies were conducted in Ccr5-/- mice that have a low basal expression of
Erdr1. Furthermore, Erdr1 expression was manipulated through bystander cells rather than
within the cancer cell. Therefore, our experiments highlight the effect of ERDR1 on the
surrounding stroma whereas the preceding references focus on the effect of ERDR1 on the
cancer cells.
The pro-metastatic and anti-metastatic properties of ERDR1 attest to the bimodal response
induced by ERDR1 (14). When the baseline expression of Erdr1 is reduced, induction of the
gene likely promotes cell survival by inhibiting apoptosis. This phenomenon was observed
during treatment with staurosporine, and is similar to our CLL data. This relationship is also
substantiated by the observation that apoptosis of melanoma cells is increased in the Ccr5-/-
mouse (12). An inverse relationship between Erdr1 expression and apoptosis has also been
demonstrated in a Nox2-/- mouse undergoing reperfusion injury (36). This model is
consistent with our data showing inhibition of Erdr1 inhibits metastasis. However, when the
transcription of Erdr1 reaches a threshold, apoptosis increases and cell viability diminishes.
This phenomenon has been demonstrated in keratinocytes that are undergoing UVB
treatment (35).
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Our experiments looked at the effects of ERDR1 as it was expressed by several cell types
including PMCs, MEFs, and M2-10B4 cells. We have seen similar results when comparing
PMCs and fibrocytes from WT and Ccr5-/- mice (37). Like our genetically manipulated
cells, cells from these animals differentially express Erdr1. In all of these experiments,
greater expression of Erdr1 in the transferred cells led to a greater the tumor burden for the
recipient.
CCR5 expression can have diverse implications for cancer prognosis depending on the
tissues that express it. In mouse models, Ccr5 boosts CD4+-dependent, CD8+ T cell
responses (38) although it may also lower infiltration by those T cells (12). Patients with
CCR5+ infiltrating lymphocytes had a better outcome in colorectal cancer (39, 40) or when
undergoing immunotherapy for melanoma (41). On the other hand, expression by the tumor
tissue is considered a poor marker in melanoma (42), prostate cancer (43) and breast cancer
(44, 45). CCR5 expression on osteosarcoma cells upregulates integrins and predisposes them
to metastasis (46). Expression of Ccr5 by the tumor fibroblasts has been associated with the
promotion of pulmonary metastasis in murine models (11, 24) and the progression of lung
cancer in patients (47). Targeting ERDR1 may be more advantageous than targeting CCR5
since it may inhibit progression mediated by the stroma without inhibiting the anti-tumor
immune response.
The study of ERDR1 in human disease is complicated by the lack of a known human
homolog. Nevertheless, the gene has been sequenced from human tissues by several labs.
ERDR1 has been detected in human keratinocytes (48), lymphoma (13), and HEK293 cells
(15). Our lab has also detected ERDR1 in nurse-like cells (49). All of these investigators
have found near sequence identity between the human and murine genes.
In summary, this paper identifies ERDR1 as a stromal-derived cytokine that promotes
cancer progression. Furthermore, it establishes an additional means by which inflammatory
chemokines contribute to cancer progression. The relationship between ERDR1 and CCR5
is clinically significant since CCR5 inhibitors are already in clinical trials (50). Further
understanding of this interaction may provide a means of separating the beneficial anti-
tumor immune responses from the harmful pro-tumor stromal support. Finally, our data
suggest that this relatively unknown gene may be critical to understanding and manipulating
tumor-stroma interactions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Erdr1 is upregulated in the lungs and PMCs of WT mice compared with Ccr5-/- mice
(A) The bar graph shows relative expression of genes from WT mice compared with Ccr5-/-
mice. Lungs were harvested 6, 24, and 48 hours after intravenous injection of B16-F10
melanoma cells. After mRNA extraction, cDNA was formed and pooled for application to
an Affymetrix GeneChip® Genome 430 Arrays (n=27). (B) Semi-quantitative RT-PCR for
Erdr1 applied to the unpooled mouse lung samples from the experiment described above.
The gel shows detectable Erdr1 mRNA for each WT mouse. (C) Semi-quantitative PCR as
applied to cDNA from four WT and four CCR5-/- mice without tumor injection. (D)
Relative Erdr1 expression in PMCs of WT and Ccr5-/- mice by real-time PCR. Gene
expression was standardized to β-actin and then was normalized to Erdr1 expression in
Ccr5-/- PMCs (n=12).
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Figure 2. Stimulation of Ccr5 on PMCs induces expression ofErdr1
(A) Erdr1 expression by real time PCR after Ccl4 treatment. WT and Ccr5-/- PMCs were
stimulated with 50 ng/ml of Ccl4 after overnight culture in serum-free media. mRNA was
harvested at 0, 24, and 48 hours. Bar graph shows expression of Erdr1 normalized to
baseline expression in WT PMCs. Significant increases in Erdr1 expression were detectable
in WT PMCs at 24 and 48 hours. No significant changes were noted in Ccr5-/- PMCs. (B)
The response of Erdr1 to Ccl4 following treatment with 10μM of the MAP2K inhibitor
U0129 and 20 μM of the PI3K inhibitor LY294002. Erdr1 expression is inhibited by U0129
(3rd bar) but not LY294002 (4th bar). (C) PMC subpopulations. The dot plot shows flow
cytometric analysis of PMC populations as defined by CD45 and Thy-1. (D) Bar graph
showing Erdr1 expression in PMCs sorted by CD45 and Thy-1. All subpopulations of WT
cells expressed more Erdr1 than Ccr5-/- (p < 0.05). (E) Bar graph shows induction of Erdr1
after stimulation with Ccl4 in PMC subpopulations. PMCs were sorted 48 hours after
treatment with 50 ng/ml of Ccl4. Only WT CD45+ PMCs exhibited a significant increase in
Erdr1 expression (p < 0.01).
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Figure 3. Inhibition ofErdr1inhibits metastasis
(A) Real-time PCR measurement of Erdr1 expression in MEFs 48 hours after transduction
with shRNA retroviral constructs. Results normalized to MEFs transduced with control
plasmid. (B) Graph showing number of B16-F10 metastases in Ccr5-/- mice injected with
MEFs transduced with control (left), shRNA&num;1 (middle), or shRNA&num;2 (right).
Mice were injected with 4×105 MEFs 24 hours before injection with 7.5 × 105 melanoma
cells. Metastases are normalized to mice treated with control MEFs; results are pooled from
three different experiments. (C) Photographs of the lungs (left upper lobe) of representative
mice described in (B). (D) Graph showing metastases in WT mice injected with control or
shRNA transduced MEFs. Results normalized to control MEF group. (E) Bar graph
representing the number of B16-F10 metastases in Ccr5-/- mice. Black bars represent mice
that received more than 50% transduced MEFs; striped bars are mice that received less than
50% transduced MEFs. The sample sizes are given just above the x-axis. (F) The graph
shows the amount of eGFP detected from the lung of Ccr5-/- injected with MEFs that had
been transduced with control or shRNA plasmids. eGFP was detected by ELISA. First
column on the left is eGFP expression in mice injected with unmanipulated MEFs. (G) Real
time PCR measurement of Erdr1 in the lung of Ccr5-/- mice 24 hours after injection with
4×105 MEFs transduced with control or shRNA. Columns on the right show Erdr1
expression of Ccr5-/- and WT mice without MEF injection.
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Figure 4. Inhibition ofErdr1promotes apoptosis of primary chronic lymphocytic leukemia cells
(A) Effect of Erdr1 knockdown on staurosporine induced apoptosis. MEFs were transduced
with Erdr1 knockdown or control shRNA and were treated with or without staurosporine
(100 nM). The bar graph shows a disproportionate increase the apoptosis of MEFs treated
with Erdr1 shRNA. The differences between control and knockdown shRNA transduced
cells were lost when the caspase inhibitor Z-VAD-FMK was added. (B) Erdr1 expression in
M2-10B4 cell lines. Results are expressed relative to the parent line (top). The bottom three
lines are stable clones transduced with non-target control, shRNA&num;1, or shRNA&num;
2 plasmids. (C) Total cell number of CLL cells co-cultured with M2-10B4 clones. Each line
represents a sample from an individual patient. The points on the left are the cell number
after culture with non-targeted control M2-10B4 cells. The points in the center and right are
numbers after culture with shRNA knockdown lines. Cells were harvested after 96 hours of
culture. (D) Representative sample dot plots of CLL samples co-cultured with M2-10B4
clones. The mean ± SEM is given for all 10 CLL samples.
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